Frequent and Early HIV-1 MN Neutralizing Capacity in Sera from Dutch HIV-1 Seroconverters Is Related to Antibody Reactivity to Peptides from the gp120 V3 Domain
Authors:
- Nicole K. T. BackNBNicole K. T. Back
- Chitra RamautarsingCRChitra Ramautarsing
- Margreeth ValkMVMargreeth Valk
- Lia van der HoekLHLia van der Hoek
- Jaap GoudsmitJGJaap Goudsmit
- 1 March 1994
- journal article
- research article
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 10 (3) , 245-251
Abstract
The temporal development of HIV-1 neutralizing activity and antibodies to the gp120-V3 neutralization domain were studied in sera from 20 Dutch HIV-1-infected individuals followed from seroconversion on. Serum neutralizing capacity was assessed with three T cell line-tropic isolates: HIV-1 MN , HIV-1 HXB2 , and the patient isolate HIV-1 320 . Neutralizing activity to HIV-1 MN developed in 18 individuals (90%) within 0 to 10 months after seroconversion. Parallel evolution of IgG reactivity to V3 peptides of United States/European type variants, and the capability of such peptides to completely inhibit HIV-1 MN neutralization in four of five tested sera (taken 1-2 years after seroconversion), indicate that a large proportion of HIV-1 MN neutralizing antibodies is directed to V3. The early appearance and high frequency of HIV-1 MN neutralizing activity in the Dutch study group indicate the close relationship of HIV-1 MN to HIV-1 variants circulating in the Netherlands. Neutralizing activity to HIV-1 HXB2 (in 15 of 20 individuals) developed several months after that to HIV-1 MN in all individuals (average, 10 months after seroconversion) and was not seen in the absence of HIV-1 MN neutralizing activity. Neutralizing activity to the Dutch isolate HIV-1 320 (found in 11 of 18 tested individuals) emerged simultaneously with that to HIV-1 MN in 4 individuals but appeared later in 7. In most individuals, HIV-1 HXB2 neutralization was not accompanied by reactivity to a V3 peptide from this strain, indicating that the extension of neutralizing activity to more divergent strains, which takes place at later stages, must be attributed to non-V3-directed antibodies.Keywords
This publication has 7 references indexed in Scilit:
- Phenotype-associated env gene variation among eight related human immunodeficiency virus type 1 clones: evidence for in vivo recombination and determinants of cytotropism outside the V3 domainJournal of Virology, 1992
- Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoproteinJournal of Virology, 1992
- Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activityJournal of Virology, 1992
- Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120Journal of Virology, 1992
- Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individualJournal of Virology, 1991
- Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzeesJournal of Virology, 1990
- Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated virusesJournal of Virology, 1987